Advertisement

Topics

Latest "Marketed Nasal Strip Placebo Nasal Strip Prototype Nasal" News Stories

21:21 EST 12th November 2018 | BioPortfolio

Here are the most relevant search results for "Marketed Nasal Strip Placebo Nasal Strip Prototype Nasal" found in our extensive news archives from over 250 global news sources.

More Information about Marketed Nasal Strip Placebo Nasal Strip Prototype Nasal on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Marketed Nasal Strip Placebo Nasal Strip Prototype Nasal for you to read. Along with our medical data and news we also list Marketed Nasal Strip Placebo Nasal Strip Prototype Nasal Clinical Trials, which are updated daily. BioPortfolio also has a large database of Marketed Nasal Strip Placebo Nasal Strip Prototype Nasal Companies for you to search.

Showing "Marketed Nasal Strip Placebo Nasal Strip Prototype Nasal" News Articles 1–25 of 2,400+

Monday 12th November 2018

Quidel to Present at the 30th Annual Piper Jaffray Healthcare Conference

Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the 30th Annual Piper Jaffray Healthcare Conference, to be held at the Lotte New York Palace hotel in New York, New York on Wednesday, November 28, 2018. Dougl...


Daily briefing: How the placebo effect actually works

Xeris Pharmaceuticals Releases Additional Phase 3 Clinical Trial Data on Its Ready-to-Use Liquid Glucagon Pen

Positive efficacy and utility data presented during the 18th Annual Diabetes Technology Meeting Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced the presentation of additional data ...


A Lateral Flow Immunochromato-graphic Strip Test for Rapid Detection of Oseltamivir Phosphate in Egg and Chicken Meat

KalVista Pharmaceuticals Provides Clinical Update on KVD900

– Enlarged Phase 2 Study to Begin in 2018 for Potential Acute Treatment of Hereditary Angioedema; Data Expected in Late 2019 – – Food Effect Study Indicates No Dosing Limitations from Food and Confirms Rapid Uptake and High Exposure – KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the d...

Concert Pharmaceuticals Reports Positive CTP-543 Results from Interim Analysis of Phase 2a Trial in Patients with Alopecia Areata

CTP-543 Achieved its Primary Endpoint in the 8 mg Twice-Daily Cohort Company to Host Investor Conference Call Today at 8:30 a.m. ET Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced interim topline results from the first two cohorts of its Phase 2a trial evaluating its investigational treatment CTP-543 in patients with moderate-to-s...

Lysulin® Hits the Market: A Breakthrough Dietary Supplement for People with Type 2 Diabetes and Prediabetes

Dexcom Founder Dr. John Burd, Ph.D. Launches Lysulin ®, an All-Natural Nutritional Support for People with Diabetes, in an Easy-To-Take Chewable Tablet SAN DIEGO (PRWEB) November 12, 2018 Lysulin, Inc. announced today the launch of Lysulin®, a first-in-class nutritional supplement formulated for people with Type 2 diabetes and prediabetes.* Lysulin provides a breakthrough, clinically st...

US FDA Accepts Regulatory Submission For LYNPARZA (olaparib) Maintenance Therapy in Newly-Diagnosed, BRCA-mutated Advanced Ovarian Cancer and Grants Priority Review

Approval would expand use of AstraZeneca and MSD’s LYNPARZA to patients in the 1st-line setting following platinum-based chemotherapy First regulatory submission acceptance for a PARP inhibitor as a 1st-line maintenance treatment for advanced ovarian cancer AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outs...

FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) Maintenance Therapy in Newly-Diagnosed, BRCA-Mutated Advanced Ovarian Cancer and Grants Priority Review

Approval Would Expand Use of AstraZeneca and Merck’s LYNPARZA to These Patients in the First-Line Setting Following Platinum-Based Chemotherapy First U.S. Regulatory Submission Acceptance for a PARP Inhibitor as a First-Line Maintenance Treatment for Certain Patients with Advanced Ovarian Cancer AstraZeneca and Merck (NYSE:MRK), known...

RoosterBio Submits U.S. FDA Master Files for CliniControl™ Line of Human Mesenchymal Stem/Stromal Cell Products

Designed to radically simplify the process of clinical translation for Regenerative Medicine companies that utilize hMSCs within their manufacturing process. FREDERICK, Md. (PRWEB) November 12, 2018 RoosterBio Inc, a leading supplier of human Mesenchymal Stem/Stromal Cell (hMSC) working cell banks and hMSC-specific bioprocess systems, announces today it has submitted a U.S. Food and Drug Administ...

Amarin's Vascepa trial stirs data debate as stock drops 10%

A five-year clinical trial showed strong heart benefits for the fish oil-based pill, but questions on the placebo used in the study have raised doubts as well.

Are placebo effects genetically determined?

We frequently write about placebo effects here at SBM because understanding placebo effects is essential to understanding a lot of clinical trial science and, most relevant to the topics of this blog, how those promoting unscientific medicine misunderstand and misuse placebo effects to promote quackery. Last week, the NYT published an article asking if placebo effects are genetically determined. T...

VALBIOTIS Announces Expansion of Application for VALEDIA to Include NASH Prevention

New results demonstrate the clinical potential of VALEDIA for NASH risk reduction. Studies on VALEDIA show complete reversion of hepatic steatosis in an in vivo preclinical model1. A mechanism of action on 3 key targets of hepatic steatosis, presented at the 2018 American Association for the Study of Liver ...

Transgene - Positive Results from Phase 1 Clinical Trial of TG1050 in Chronic Hepatitis B Presented at the AASLD Liver Meeting 2018

Primary end-point reached: safety established following single dose and multiple doses administration of TG1050 in chronic hepatitis B patients under antiviral (NUC) therapy TG1050 triggers T cell-based immune responses, specific of all 3 encoded HBV antigens, confirming the mechanism of action of the product ...

Sunday 11th November 2018

Vascepa Vs Placebo: AMRN Stands Behind REDUCE-IT Results

Amarin Corp. plc (AMRN), on Saturday, presented impressive primary results from its Vascepa cardiovascular outcomes trial, dubbed REDUCE-IT, at the 2018 Scientific Sessions of the American Heart Association in Chicago, Illinois. The study findings were simultaneously published in The New England Journal of Medicine.

University of Dundee Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 12102018] Prices from USD $250

SummaryUniversity of Dundee Dundee is an educational service provider that offers a range of undergraduate, postgraduate, postgraduate research degree and distant learning programs. The university offers a wide range of academic and research courses in various disciplines such as accounting, arts, philosophy, law, language, engineering, economics, medicine, healthcare, finance and biochemistry, am...

AstraZeneca reports positive results from type-2 diabetes drug trial

AstraZeneca has reported positive results from the DECLARE-TIMI 58 trial that evaluated the efficacy of farxiga against placebo in adults...Read More... The post AstraZeneca reports positive results from type-2 diabetes drug trial appeared first on Drug Development Technology.

Deep knowledge AI system could speed up drug research

Researchers from the University of Waterloo have developed a system that could significantly speed up the discovery of new drugs, reducing the need for costly and time-consuming laboratory tests. Known as Pattern to Knowledge (P2K) and described in the journal Scientific Reports, the new technology uses artificial intelligence (AI) to leverage deep knowledge from data instead of relying solely on...

Well-Funded Unicorn Moderna Therapeutics Eyes $500 Million IPO

As a private company, Moderna has amassed a significant fortune of billions of dollars and a valuation of about $7 billion – all of this without any marketed product in the company’s field of messenger RNA (mRNA).

Acucela Initiates Phase 3 Study of Emixustat Addressing Patients with Stargardt Disease

Acucela Inc. (“Acucela”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today that on November 7, 2018, the first patient has enrolled (FPFV; first patient first visit) in a study to evaluate Acucela’s leading drug candidate, emixustat hydrochloride (“emixustat...

AHA: Novel Agent Promising for Lowering Lp(a) Levels

(MedPage Today) -- Treatment with AKCEA-APO(a)-LRx better than placebo at multiple doses

Jiangsu Yuyue Medical Equipment Supply Co Ltd 002223 Medical Equipment Deals and Alliances Profile [Report Updated: 16102018] Prices from USD $250

SummaryJiangsu Yuyue Medical Equipment Supply Co Ltd Jiangsu Yuyue is a medical device company that manufactures and distributes various medical equipments. The company's products include electronic blood pressure monitor, air sterilization purifier, Xray machine, blood glucose meter, temperature diagnostic system, oxygen concentrator, insulin needle, blood pressure monitor, stethoscope, universa...

Detailed results from a clinical trial showed Amarin fish oil significantly reduced the risk of cardiovascular events compared with a placebo — but it came with a controversial blemish. https://buff.ly/2zM0P7k 

Detailed results from a clinical trial showed Amarin fish oil significantly reduced the risk of cardiovascular events compared with a placebo — but it came with a controversial blemish. https://buff.ly/2zM0P7k 

United States Respiratory Device Accessories Market Outlook to 2025 [Report Updated: 03102018] Prices from USD $4995

United States Respiratory Device Accessories Market Outlook to 2025SummaryGlobalData's new report, United States Respiratory Device Accessories Market Outlook to 2025, provides key market data on the United States Respiratory Device Accessories market. The report provides value, in millions of US dollars, volume in units and average prices USD within market segments Aerosol Masks, CardioPulmonary...

Saturday 10th November 2018

An anti-inflammatory drug used to treat rheumatoid arthritis worked no better than placebo in preventing another cardiovascular event in people at risk. https://buff.ly/2Qx9txL 

An anti-inflammatory drug used to treat rheumatoid arthritis worked no better than placebo in preventing another cardiovascular event in people at risk. https://buff.ly/2Qx9txL 


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks